Taking a close look at the behavior of each patient, we could observe that all patients restored the NET degradation ability with the addition of rhDNaseI, suggesting that the NET degradation impairment of BC patients is not caused by DNaseI inhibitors or anti-NET antibodies (Figure 8). Here, DNASE1 is linked to breast cancer.